GLUE · Monte Rosa Therapeutics, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $44.07M | - | $36.68M | $30.65M | $32.19M | - | $27.62M | $28.05M | $27.03M | - |
| SG&A | $10.18M | - | $9.06M | $8.10M | $8.70M | - | $8.13M | $9.28M | $8.98M | - |
| Total Operating Expenses | $54.24M | - | $45.74M | $38.75M | $40.89M | - | $35.74M | $37.34M | $36.01M | - |
| D&A | $2.03M | - | $2.10M | $2.13M | $2.05M | - | $2.10M | $2.06M | $1.90M | - |
| Operating Income | ($50.03M) | - | ($32.98M) | ($15.55M) | $44.04M | - | ($26.53M) | ($32.64M) | ($34.95M) | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | $52.0K | - | ($3.18M) | $1.20M | $822.0K | - | $71.0K | $252.0K | $83.0K | - |
| Net Income | ($44.50M) | - | ($27.08M) | ($12.29M) | $46.88M | - | ($23.86M) | ($30.31M) | ($31.97M) | - |
| EPS - Basic | - | - | - | - | - | - | - | - | - | - |
| EPS - Diluted | - | - | - | - | - | - | - | - | - | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $159.86M | $129.88M | $208.34M | $69.43M | $78.53M | $224.25M | $125.58M | $108.85M | $99.75M | $128.10M |
| Accounts Receivable | - | - | - | - | - | - | - | $9.00M | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $7.90M | $3.55M | $14.51M | $5.58M | $6.49M | $17.21M | $3.98M | $6.47M | $6.83M | $11.15M |
| Current Assets | $677.55M | $393.19M | $401.82M | $299.46M | $332.28M | $377.44M | $251.21M | $277.90M | $199.04M | $236.21M |
| Total Assets | $736.43M | $448.66M | $459.84M | $359.59M | $393.20M | $438.73M | $315.08M | $344.11M | $266.75M | $303.75M |
| Current Liabilities | $71.04M | $64.21M | $61.44M | $41.85M | $59.22M | $156.95M | $41.64M | $42.35M | $41.29M | $46.59M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $214.51M | $215.60M | $214.00M | $91.51M | $118.04M | $215.80M | $109.62M | $119.44M | $114.23M | $124.50M |
| Stockholders' Equity | $521.92M | $233.06M | $245.84M | $268.08M | $275.16M | $222.94M | $205.46M | $224.67M | $152.52M | $179.25M |
| Retained Earnings | ($521.72M) | ($477.21M) | ($431.08M) | ($404.00M) | ($391.70M) | ($438.59M) | ($452.02M) | ($428.17M) | ($397.86M) | ($365.89M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($37.37M) | - | - | - | ($45.49M) | - | - | - | ($38.16M) | - |
| Investing Cash Flow | ($261.00M) | - | - | - | ($100.23M) | - | - | - | $9.85M | - |
| Financing Cash Flow | $328.33M | - | - | - | $14.0K | - | - | - | $246.0K | - |
| CapEx | $1.87M | - | - | - | $1.59M | - | - | - | $1.38M | - |
| Free Cash Flow | ($39.24M) | - | - | - | ($47.08M) | - | - | - | ($39.55M) | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | 0.88 | - | - | - | -1.00 | - | - | - | 1.24 | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | 1.7% | - | - | - | - | - |
| Return on assets | -6.0% | - | -5.9% | -3.4% | 11.9% | - | -7.6% | -8.8% | -12.0% | - |
| Return on equity | -8.5% | - | -11.0% | -4.6% | 17.0% | - | -11.6% | -13.5% | -21.0% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 9.54 | 6.12 | 6.54 | 7.16 | 5.61 | 2.40 | 6.03 | 6.56 | 4.82 | 5.07 |
| Quick ratio | 9.54 | 6.12 | 6.54 | 7.16 | 5.61 | 2.40 | 6.03 | 6.56 | 4.82 | 5.07 |
| Cash ratio | 2.25 | 2.02 | 3.39 | 1.66 | 1.33 | 1.43 | 3.02 | 2.57 | 2.42 | 2.75 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 1.41 | 1.93 | 1.87 | 1.34 | 1.43 | 1.97 | 1.53 | 1.53 | 1.75 | 1.69 |
| Liabilities / Assets | 0.29 | 0.48 | 0.47 | 0.25 | 0.30 | 0.49 | 0.35 | 0.35 | 0.43 | 0.41 |
| Efficiency | ||||||||||
| Asset turnover | - | - | - | - | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | 3.1x | - | 2.5x | 1.4x | 1.4x | - | 2.1x | 1.2x | 2.8x | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | 6.6x | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | - | - | -24.3% | 52.3% | - | - | 28.2% | 12.3% | -2.0% | - |
| Net income growth (YoY) | - | - | -13.5% | 59.4% | - | - | 31.6% | 13.8% | 0.2% | - |
| EPS growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | 16.7% | - | - | - | -19.0% | - | - | - | -21.4% | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | 89.7% | 4.5% | 19.7% | 19.3% | 80.4% | 24.4% | 11.3% | 5.2% | -37.4% | -34.0% |
Peer comparison
Same SIC group: Biological Products, (No Diagnostic Substances)
Comparing Monte Rosa Therapeutics against the 5 most active filers in the same SIC group.